X

NSCLC

NSCLC

Expert Roundtable: Exploring the Treatment Landscape of KRAS G12C-Mutated NSCLC

In part one of this roundtable discussion, Dr Melina Marmarelis, Dr Lova Sun, and Dr Hossein Borghaei, sat down with OLN to discuss KRAS G12C sensitive mutations in patients with lung cancer.

09/29/2021
Expert Roundtable: Overcoming Resistance in KRAS G12C-Mutated NSCLC

In part two of this roundtable discussion, Dr Melina Marmarelis, Dr Lova Sun, and Dr Hossein Borghaei, sat down with OLN to discuss overcoming resistance to KRAS G12C sensitive mutations in...

09/29/2021
Expert Roundtable: OS Rates Among Patients With EGFR Mutations in the TKI Era

In part one of this roundtable discussion moderated by Dr Edgardo Santos, a panel of experts sat down with Oncology Learning Network to discuss the rates of OS among patients with EGFR mutations...

10/27/2021

Expert Roundtable: Biologic Differences Among EGFR/ERBB1 Mutations in Patients With Lung Cancer

In part two of this roundtable discussion, moderated by Dr Edgardo Santos, a panel of experts sat down with Oncology Learning Network to discuss the biological differences among EGFR/ERBB1 mutation

10/27/2021
Expert Roundtable: The Management and Care of EGFR Patients

In part three of this virtual roundtable discussion, moderated by Dr Edgardo Santos, a panel of experts sat down with Oncology Learning Network to discuss the management and care of EGFR patients.<

10/28/2021
Lung Cancer and Immunotherapy With Dr. Patrick Forde and Oswald Peterson

Dr Patrick Forde is joined by lung cancer veteran, Oswald Peterson, to discuss several recently approved immunotherapy options and how immunotherapy is advancing the treatment of lung cancer.

10/22/2021
ZENITH20-4: Efficacy & Safety of Poziotinib in Treatment-Naïve NSCLC With HER2 Exon 20 Mutations

Dr Robin Cornelissen presents the results from the ZENITH20-4 study which evaluates the efficacy and safety of poziotinib in newly diagnosed patients with NSCLC and HER2 exon 20 insertion mutations.

10/05/2021
Predicting Outcomes of Advanced NSCLC Patients Treated With PD-1/PDL

Dr Gilberto de Lima Lopes Jr discusses "Predicting Outcomes of Advanced NSCLC Patients Treated With PD-1/PDL."

09/03/2021
Sotorasib For KRAS G12C-Mutated Lung Cancer

Dr Sarah B. Goldberg discusses sotorasib for KRAS G12C-Mutated lung cancer.

08/24/2021
5-Year Survival Outcomes From The PACIFIC Trial

Dr David R. Spigel presents five-year survival outcomes from the PACIFIC trial, a placebo-controlled Phase III study of patients with unresectable stage III NSCLC who were treated with durvalumab.

06/05/2021
Surgical Endpoints Are Needed in Lung Cancer Trials of Neoadjuvant Therapy

Dr Jonathan Spicer highlights the importance of introducing new endpoints in clinical trials of neoadjuvant approaches for lung cancer.

07/19/2021
Lung Cancer Trial Updates at ASCO 2021

Dr Benjamin Besse discusses results from lung cancer trials that are anticipated in 2021.

06/23/2021
WCLC 2020: Updates From the CHRYSALIS Trial And What it Means for Patients With NSCLC

In this expert discussion Dr Joshua Bauml and Dr Joshua Sabari speak about the updates from the CHRYSALIS trial and what it means for patients with NSCLC.

08/02/2021
PIPSeN Trial: Olaparib Maintenance vs Placebo in Platinum-Sensitive NSCLC

Dr Sophie Postel-Vinay speaks about the PIPSeN trial, a randomized, double-blind phase II study that evaluated the PARPi olaparib as maintenance treatment in patients with platinum-sensitive advanced NSCLC.

07/28/2021
Surgical Outcomes From the Phase III CheckMate 816 Trial

Dr Jonathan Spicer outlines surgical outcomes from CheckMate 816, a Phase III study evaluating nivolumab and platinum-doublet CT versus CT alone as neoadjuvant treatment for patients with resectable NSCLC.

07/19/2021
Osimertinib + Ipilimumab in EGFR-Mutated NSCLC

Dr Sonam Puri discusses a trial which explores the combination of osimertinib, an EGFR TKI with ipilimumab, a monoclonal antibody drug in patients with EGFR mutant NSCLC as first line treatment.

07/08/2021
Disease-Free Survival in IMpower010 Trial: Adjuvant Atezolizumab in NSCLC

Dr Sanjay Popat discusses results of the IMpower010 trial in patients with version 7 TNM, stage 1b resected non-small cell lung cancer.

07/02/2021
Bispecific Antibodies in Lung Cancer

Dr Benjamin Besse outlines the role of bispecific antibodies in treating lung cancer.

06/18/2021
IMpower010: Adjuvant Atezolizumab Improves DFS in Resected Stage II-IIIA NSCLC

Dr Heather Wakelee talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA NSCLC.

06/16/2021
Candid Conversations in Lung Cancer: Discussing Biomarker Testing and Targeted Therapies

PeerView has partnered with the LUNGevity foundation to bring the patient perspective into education directed to oncology and pathology professionals, and highlight the importance of having open conversations...

06/12/2021
Checkpoint Inhibitors - Alone or With Chemotherapy in Lung Cancer?

Should patients with lung cancer with high PD-L1 expression be treated with checkpoint inhibitors alone or a combined checkpoint inhibitor and chemotherapy regimen? Dr Bruna Pellini highlights this as a major unanswered question in the field.

06/04/2021
Evolving Applications of ctDNA in Lung Cancer: MRD, Early Detection, and Molecular Profiling

Dr Vamsidhar Velcheti outlines some of the evolving uses of ctDNA in lung cancer including molecular profiling, early disease detection, and relapse prediction.

06/04/2021
Immunotherapy as a Game-Changer in Multimodal Management of Lung Cancer

Chair, Dr Brendon M. Stiles, Dr Boris Sepesi, and Dr Catherine Shu discuss immunotherapy advances in lung cancer in this presentation.

05/27/2021
Lung Cancer Nursing UK Session at BTOG

Dr Catherine Henshall discusses the session on lung cancer nursing in the UK which took place at BTOG 2021.

05/17/2021
No One Missed—NSCLC Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate treatment...

05/03/2021
Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Dr Patrick Y. Wen discusses adjuvant osimertinib in resected EGFR-Mutated NSCLC.

05/01/2021
Novel Therapies on the Horizon for Lung Cancer

Dr Samreen Ahmed discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer.

04/29/2021
Multisystem Immune-Related AEs With Immunotherapy in NSCLC

Jarushka Naidoo gives an overview of a study investigating immune-related adverse events associated with immune checkpoint inhibitor therapy for the treatment of NSCLC.

04/26/2021
NERO Trial: PARP Inhibitors for Chemosensitive NSCLC

Dr Dean Fennell shares an update on the randomized Phase II/III NERO study investigating PARP inhibitors in patients with NSCLC who have previously responded to chemotherapy.

04/20/2021
Antibiotics Impact Outcomes With Pembrolizumab in NSCLC Patients

Dr David Pinato outlines the impact of host determinants on response to immunotherapy in patients with NSCLC, highlighting PD-L1 expression as a biomarker for pembrolizumab response.

04/20/2021
Guideline-Recommended Molecular Testing in Early-Stage NSCLC

This is a multidisciplinary look at molecular testing in early-stage non-small cell lung cancer.

03/09/2021
Using Clinical Trials to Drive Treatment Approaches in Lung Cancer

Dr Andrew Robinson discusses the importance of using clinical trials to drive treatment approaches and summarizes the role of immunotherapies in the treatment of squamous NSCLC...

04/12/2021
Systemic Treatment of Non-Oncogene Addicted NSCLC With Brain Metastases

Dr Lizza Hendriks discusses the systemic treatment of patients with non-small cell lung cancer and brain metastases who are non-oncogene addicted.

03/26/2021

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834